公开(公告)号：US12234272B2

公开(公告)日：2025-02-25

申请号：US17709296

申请日：2022-03-30

Applicant: Ferring B.V.

Inventor： Ian Cottingham ,  Daniel Plaksin ,  Richard White

IPC: C07K14/575 ,  A61K38/16 ,  C07K14/59 ,  C12P21/00

Abstract: Described are pharmaceutical compositions comprising recombinant human chorionic gonadotropin (hCG) and optionally follicle stimulating hormone (FSH), wherein the recombinant hCG in the composition comprises α2,3- and α2,6-sialylation and comprises mono-(1S), di-(2S), tri-(3S) and tetra-(4S) sialylated glycan structures. The recombinant hCG may be obtained by expression in a human cell line, such as the PER.C6 cell line, optionally wherein the cell line is modified using α2,3-sialyltransferase.

公开(公告)号：US11292824B2

公开(公告)日：2022-04-05

申请号：US16709810

申请日：2019-12-10

Applicant: Ferring B.V.

Inventor： Ian Cottingham ,  Daniel Plaksin ,  Richard White

IPC: C07K14/575 ,  C07K14/59 ,  C12P21/00 ,  A61K38/16

Abstract: Described are pharmaceutical compositions comprising recombinant human chorionic gonadotropin (hCG) and follicle stimulating hormone (FSH), wherein the recombinant hCG in the composition comprises α2,3- and α2,6-sialylation and comprises mono-(1S), di-(2S), tri-(3S) and tetra-(4S) sialylated glycan structures. The recombinant hCG may be obtained by expression in a human cell line, such as the PER.C6 cell line, optionally wherein the cell line is modified using α2,3-sialyltransferase.